Disclosures for "Reduced Clinical Deteriorations and Healthcare Resource Utilization After Switching from Efgartigimod to Ravulizumab in Patients with Generalized Myasthenia Gravis in the United States"
-
Dr. Stein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Argenx. Dr. Stein has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for UCB. Dr. Stein has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Immunovant. Dr. Stein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Stein has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Johnson & Johnson . Dr. Stein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Argenx. Dr. Stein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Amgen. Dr. Stein has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for UCB. Dr. Stein has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Johnson & Johnson.
-
Dr. Caraballo-Cartagena has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Caraballo-Cartagena has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx. Dr. Caraballo-Cartagena has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Caraballo-Cartagena has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for UCB. Dr. Caraballo-Cartagena has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Alexion. Dr. Caraballo-Cartagena has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Takeda. Dr. Caraballo-Cartagena has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Alnylam. Dr. Caraballo-Cartagena has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Argenx.
-
Dr. Blackowicz has received personal compensation for serving as an employee of Alexion Pharmaceuticals. Dr. Blackowicz has stock in Alexion Pharmaceuticals.
-
Dr. Weiskopf has received personal compensation for serving as an employee of Alexion AstraZeneca Rare Disease. Dr. Weiskopf has or had stock in Alexion Astrazeneca Rare Disease.
-
Rebecca Novak has received personal compensation for serving as an employee of Veeva Systems Inc.
-
Dr. Zhang has received personal compensation for serving as an employee of Veeva Systems.
-
Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Alexion. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for CSL Behring . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Argenx Pharmaceuticals. Dr. Scheiner has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Jansssen. Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for CSL Behring . Dr. Scheiner has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Alexion Pharmaceuticals . Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Amgen. Dr. Scheiner has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Janssen. The institution of Dr. Scheiner has received research support from Alexion Pharmaceuticals .